Results of the HERS, ERA, and WHI trials suggest a conservative approach to use of HRT in women with evidence of CHD. Dose and duration of therapy may be key to the risk-benefit equation.
Low creatinine-to-cystatin C ratio linked to postmenopausal muscle loss
March 20th 2025A new study finds that postmenopausal women with a reduced creatinine-to-cystatin C ratio experience decreased muscle volume and slower walking speed, highlighting its role as a potential biomarker for muscle health.
Read More